Lexeo TherapeuticsLXEO +5.39%10 Return-on-Tangible-Equity is -33.79% as of Mar. 2026. GuruFocus rates LXEO with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 1,196 Biotechnology companies, Lexeo Therapeutics ranks worse than 55.77% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Lexeo Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-80.78 Mil. Lexeo Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $239.08 Mil. Therefore, Lexeo Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -33.79%.
The historical rank and industry rank for Lexeo Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
LXEO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -22855.08 Med: -85.37 Max: -53.01
Current: -53.01
During the past 6 years, Lexeo Therapeutics's highest Return-on-Tangible-Equity was -53.01%. The lowest was -22,855.08%. And the median was -85.37%.
LXEO's Return-on-Tangible-Equity is ranked worse than 55.77% of 1196
companies
in the Biotechnology industry
Industry Median: -42.305
vs LXEO: -53.01
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Lexeo Therapeutics Return-on-Tangible-Equity Related Terms
Lexeo Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Lexeo Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LXEO vs PROK, CMPX, XFOR: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Lexeo Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexeo Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -33.79% mean?
Lexeo Therapeutics (LXEO) has a Return-on-Tangible-Equity of -33.79% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lexeo Therapeutics and its competitors. According to the industry distribution chart, Lexeo Therapeutics ranks #667 out of 1196 companies in the Biotechnology industry, placing it in the top 55.8%.
Is Lexeo Therapeutics' Return-on-Tangible-Equity too high?
Lexeo Therapeutics' current Return-on-Tangible-Equity is -33.79%. Based on the distribution chart, Lexeo Therapeutics ranks #667 out of 1196 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lexeo Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Lexeo Therapeutics' Return-on-Tangible-Equity compare to PROK and CMPX?
According to the Biotechnology industry distribution chart, Lexeo Therapeutics ranks #667 out of 1196 companies for Return-on-Tangible-Equity. This places Lexeo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lexeo Therapeutics and its competitors. Lexeo Therapeutics's current Return-on-Tangible-Equity is -33.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexeo Therapeutics stock overvalued right now?
Lexeo Therapeutics (LXEO) has a current Return-on-Tangible-Equity of -33.79%. The current Return-on-Tangible-Equity is -33.79%. Lexeo Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Lexeo Therapeutics (LXEO), the current Return-on-Tangible-Equity is -33.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
10GF Score
Get the complete analysis for LXEO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LXEO has been successfully added to your 
